Decitabine/Cedazuridine: First Approval.

ABSTRACT: A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi^®), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals) for the treatment of various cancers like myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemia (AML), glioma and solid tumours. Decitabine, a DNA methyltransferase inhibitor approved for the treatment of MDS and CMML, is degraded by cytidine deaminase in the gastrointestinal tract and liver, thereby limiting oral bioavailability. Cedazuridine is a proprietary, patented cytidine deaminase inhibitor that, when added to decitabine, increases oral bioavailability of the drug. In July 2020, decitabine/cedazuridine received its first approval in the USA and Canada for the treatmen

SUBMITTER: Dhillon S 

PROVIDER: S-EPMC7708383 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature